{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:51:05Z","timestamp":1791237065517,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pericardial effusion is a common finding in advanced-stage lung cancer. The presence of malignant cells or\u00a0drainage of exudate effusion in the pericardial space may cause symptoms of dyspnea, pleuritic chest pain, and syncope. In addition to the difficulty physicians\u00a0face in\u00a0the\u00a0detection and diagnosis of malignant pericardial effusion, treatment may be challenging\u00a0considering the cancer prognosis and cardiovascular stability of the patient. Despite the\u00a0availability of\u00a0several treatment modalities for malignant pericardial effusion, including chemotherapy and surgery, patients with lung cancer historically present with poor\u00a0prognoses. In addition to lung adenocarcinoma with malignant pericardial effusion, this case\u00a0was\u00a0complicated by COVID-19 and\u00a0malignancy-associated\u00a0obstructive pneumonia. We present\u00a0a\u00a0case of a 64-year-old\u00a0woman with advanced non-small cell lung carcinoma (NSCLC) with malignant pericardial effusion who, despite testing positive for COVID-19 and having obstructive pneumonia, had favorable\u00a0outcomes\u00a0following systemic therapy with combined chemo-immunotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2022.871132","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T02:54:06Z","timestamp":1651805646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion?"],"prefix":"10.3389","volume":"12","author":[{"given":"Varsha","family":"Chiruvella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asad","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Islam","family":"Elhelf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagla Abdel","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/01.md.0000199556.69588.8e","article-title":"Large Symptomatic Pericardial Effusion as the Presentation of Unrecognized Cancer: A Study in 173 Consecutive Patients Undergoing Pericardiocentesis","volume":"85","author":"Ben-Horin","year":"2006","journal-title":"Med (Baltimore)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90262-N","article-title":"Etiology of Large Pericardial Effusions","volume":"95","author":"Corey","year":"1993","journal-title":"Am J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(81)90159-5","article-title":"Pericardial Disease in Patients With Cancer. The Differentiation of Malignant From Idiopathic and Radiation-Induced Pericarditis","volume":"71","author":"Posner","year":"1981","journal-title":"Am J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870715)60:2<263::AID-CNCR2820600225>3.0.CO;2-N","article-title":"Pericardial Effusion in Women With Breast Cancer","volume":"60","author":"Buck","year":"1987","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900315)65:6<1456::AID-CNCR2820650634>3.0.CO;2-5","article-title":"Cardiac Metastases","volume":"65","author":"Klatt","year":"1990","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318164545d","article-title":"Validation Study of the Proposed IASLC Staging Revisions of the T4 and M Non-Small Cell Lung Cancer Descriptors Using Data From 23,583 Patients in the California Cancer Registry","volume":"3","author":"Ou","year":"2008","journal-title":"J Thorac Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs372","article-title":"Management of Pericardial Effusion","volume":"34","author":"Imazio","year":"2013","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2014.5.4.5","article-title":"Management of Malignant Pericardial Effusion","volume":"5","author":"Petrofsky","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-224771","article-title":"Total Electrical Alternans in a Patient With Malignant Pericardial Tamponade","volume":"2018","author":"Verlaan","year":"2018","journal-title":"BMJ Case Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.110.2.318","article-title":"The Diagnosis of Pericardial Effusion and Cardiac Tamponade by 12-Lead ECG","volume":"110","author":"Eisenberg","year":"1996","journal-title":"A Technol assessment Chest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.104.5.1422","article-title":"Electrocardiographic Changes in Pericardial Effusion","volume":"104","author":"Meyers","year":"1993","journal-title":"Chest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv318","article-title":"ESC Guidelines for the Diagnosis and Management of Pericardial Diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS)","volume":"36","author":"Adler","year":"2015","journal-title":"Eur Heart J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4081\/cp.2011.e38","article-title":"Survival Post Surgery for Malignant Pericardial Effusion","volume":"1","author":"Nguyen","year":"2011","journal-title":"Clin Pract"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217007","article-title":"Prognostic Factors and Nomogram for Cancer-Specific Death in Non Small Cell Lung Cancer With Malignant Pericardial Effusion","volume":"14","author":"Hu","year":"2019","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.9573","article-title":"Survival Outcome of Cancer Patients With Pericardial Effusions","volume":"33","author":"Haddad","year":"2015","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-006-9073-1","article-title":"Surgical Management of Symptomatic Pericardial Effusion in Patients With Solid Malignancies","volume":"13","author":"Gross","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"B17","article-title":"Which Treatment in Pericardial Effusion","volume":"43","author":"Campione","year":"2002","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.12.009","article-title":"Pericardial Effusions: Causes, Diagnosis, and Management","volume":"59","author":"Vakamudi","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1075.116710","article-title":"Pericardial-Peritoneal Window: A Novel Palliative Treatment for Malignant and Recurrent Cardiac Tamponade","volume":"19","author":"Kallianpur","year":"2013","journal-title":"Indian J Palliat Care"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing Cancer Patients During the COVID-19 Pandemic: An ESMO Multidisciplinary Expert Consensus","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30392-2","article-title":"Effect of Delays in the 2-Week-Wait Cancer Referral Pathway During the COVID-19 Pandemic on Cancer Survival in the UK: A Modelling Study","volume":"21","author":"Sud","year":"2020","journal-title":"Lancet Oncol"},{"key":"B22","article-title":"Managing Malignant Pericardial Effusion","volume":"150","author":"Buzaid","year":"1989","journal-title":"West J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4065\/75.3.248","article-title":"Outcomes of Primary and Secondary Treatment of Pericardial Effusion in Patients With Malignancy","volume":"75","author":"Tsang","year":"2000","journal-title":"Mayo Clin Proc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v2.i9.270","article-title":"Neoplastic Pericardial Disease: Old and Current Strategies for Diagnosis and Management","volume":"2","author":"Lestuzzi","year":"2010","journal-title":"World J Cardiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1378\/chest.126.5.1412","article-title":"Long-Term Results of Intrapericardial Chemotherapeutic Treatment of Malignant Pericardial Effusions With Thiotepa","volume":"126","author":"Martinoni","year":"2004","journal-title":"Chest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2014.04.031","article-title":"Systemic Chemotherapy in Combination With Pericardial Window has Better Outcomes in Malignant Pericardial Effusions","volume":"148","author":"Celik","year":"2014","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2010.42.4.210","article-title":"Clinical Characteristics of Malignant Pericardial Effusion Associated With Recurrence and Survival","volume":"42","author":"Kim","year":"2010","journal-title":"Cancer Res Treat"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13399","article-title":"Pericardial Tamponade During Pembrolizumab Treatment in a Patient With Advanced Lung Adenocarcinoma: A Case Report and Review of the Literature","volume":"11","author":"Harada","year":"2020","journal-title":"Thorac Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative Management of Nivolumab-Induced Pericardial Effusion: A Case Report and Review of Literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp Hematol Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.08.023","article-title":"Pericardial Effusion With Tamponade Physiology Induced by Nivolumab","volume":"222","author":"Nesfeder","year":"2016","journal-title":"Int J Cardiol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000447053","article-title":"Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion","volume":"136","author":"Kushnir","year":"2017","journal-title":"Cardiology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.05.010","article-title":"Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature","volume":"19","author":"Vittorio","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent Pleural Effusions and Cardiac Tamponade as Possible Manifestations of Pseudoprogression Associated With Nivolumab Therapy- a Report of Two Cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0507","article-title":"FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"B35","unstructured":"The New York Times. Coronavirus World Map: Tracking the Global Outbreak: The New York Times2021"},{"key":"B36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.05.034","article-title":"Covid-19 and Lung Cancer: A Greater Fatality Rate","volume":"146","author":"Rogado","year":"2020","journal-title":"Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ejca.2020.08.011","article-title":"Mortality in Patients With Cancer and Coronavirus Disease 2019: A Systematic Review and Pooled Analysis of 52 Studies","volume":"139","author":"Saini","year":"2020","journal-title":"Eur J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.annonc.2020.03.296","article-title":"Clinical Characteristics of COVID-19-Infected Cancer Patients: A Retrospective Case Study in Three Hospitals Within Wuhan, China","volume":"31","author":"Zhang","year":"2020","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer Patients in SARS-CoV-2 Infection: A Nationwide Analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01777","article-title":"Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid","volume":"10","author":"Calles","year":"2020","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.08.002","article-title":"Tocilizumab for COVID-19 Pneumonia in a Patient With Non-Small-Cell Lung Cancer Treated With Chemoimmunotherapy","volume":"22","author":"Bonomi","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.26355\/eurrev_202004_20871","article-title":"SARS-CoV-2 Causing Pneumonia-Associated Respiratory Disorder (COVID-19): Diagnostic and Proposed Therapeutic Options","volume":"24","author":"Chakraborty","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06033-2","article-title":"COVID-19 Pneumonia: Different Respiratory Treatments for Different Phenotypes","volume":"46","author":"Gattinoni","year":"2020","journal-title":"Intensive Care Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0362-6","article-title":"Cancer, COVID-19 and the Precautionary Principle: Prioritizing Treatment During a Global Pandemic","volume":"17","author":"Hanna","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1470-2045(20)30619-7","article-title":"The Effect of Clinical Decision Making for Initiation of Systemic Anticancer Treatments in Response to the COVID-19 Pandemic in England: A Retrospective Analysis","volume":"22","author":"Clark","year":"2021","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0874-8","article-title":"Caring for Patients With Cancer in the COVID-19 Era","volume":"26","author":"van de Haar","year":"2020","journal-title":"Nat Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.871132\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T02:54:10Z","timestamp":1651805650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.871132\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":46,"alternative-id":["10.3389\/fonc.2022.871132"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.871132","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"article-number":"871132"}}